Skip to main content

JoPPP series on access to medicines, pricing, generics, biologics

Series Editors: Andy Gray, Fatima Suleman, Zaheer-Ud-Din Babar

The Journal of Pharmaceutical Policy and Practice (formerly known as Southern Med Review) provides a platform for researchers to disseminate empirical research findings, with the aim that people everywhere have access to the medicines they need and use them rationally. The Journal encompasses all aspects of pharmacy including policy development, clinical, social, administrative or economic, and provides a platform to researchers, academics and practitioners from around the world to share new evidence, concerns and perspectives.

To mark the 10th anniversary of its founding, the Journal is pleased to present a themed series on the broad topic of access to medicines, including papers that deal with medicine policy, pricing, access to generics and follow-on biologics (biosimilars), as well as high priced medicines in all settings.

  1. Globally, non-communicable diseases (NCDs) are recognised as a leading cause of morbidity and mortality. Medications and medicines optimisation play an important role in the management of modifiable physiologi...

    Authors: Mohamed Ahmed Syed, Ahmed Sameer Al Nuaimi, Hamda Abdulla A/Qotba, Abduljaleel Abdullatif Zainel, Tamara Marji and Uzma Razaq
    Citation: Journal of Pharmaceutical Policy and Practice 2021 14:67
    Content type: Short report Published on:

  2. To strengthen medicines management capacity, including supply chain management, at public sector health facilities in Uganda, the Ministry of Health introduced a multipronged supervision, performance assessmen...

    Authors: Denis Okidi Ladwar, Moses Nixon Sembatya, Nancy Miriam Amony, Morries Seru, Dennis Ross-Degnan, Laura Garabedian and Birna Trap
    Citation: Journal of Pharmaceutical Policy and Practice 2021 14:14
    Content type: Research Published on:

  3. This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinica...

    Authors: Vesa Halimi, Armond Daci, Simona Stojanovska, Irina Panovska-Stavridis, Milena Stevanovic, Venko Filipce and Aleksandra Grozdanova
    Citation: Journal of Pharmaceutical Policy and Practice 2020 13:16
    Content type: Commentary Published on:

  4. In recent years, there has been increasing pressure on public health systems in high-income countries due to high medicines prices, one of the underlying causes of which are the market monopolies granted to ph...

    Authors: Yuanqiong Hu, Dimitri Eynikel, Pascale Boulet and Gaelle Krikorian
    Citation: Journal of Pharmaceutical Policy and Practice 2020 13:1
    Content type: Review Published on:

  7. The availability of medicines in public health facilities in Tanzania is problematic. Medicines shortages are often caused by unavailability at Medical Stores Department, the national supplier for public healt...

    Authors: Karin Wiedenmayer, Romuald Mbwasi, William Mfuko, Ezekiel Mpuya, James Charles, Fiona Chilunda, Denis Mbepera and Ntuli Kapologwe
    Citation: Journal of Pharmaceutical Policy and Practice 2019 12:4
    Content type: Research Published on:

  8. High medicines prices increasingly pose challenges for universal access to treatments of communicable and non-communicable diseases. New essential medicines are often patent-protected which sustains high price...

    Authors: Ellen F. M. ‘t Hoen, Tapiwanashe Kujinga and Pascale Boulet
    Citation: Journal of Pharmaceutical Policy and Practice 2018 11:31
    Content type: Review Published on:

  9. In the United States (U.S.), large price increases for selected generic drugs have elicited public outrage. Recent legislative proposals aim to increase price transparency and identify outlier drug “price spik...

    Authors: Rena M. Conti, Kevin H. Nguyen and Meredith B. Rosenthal
    Citation: Journal of Pharmaceutical Policy and Practice 2018 11:29
    Content type: Research Published on:

  10. Canadians have long been proud of their universal health insurance system, which publicly funds the cost of physician visits and hospitalizations at the point of care. Prescription drugs however, have been sub...

    Authors: Jaden Brandt, Brenna Shearer and Steven G. Morgan
    Citation: Journal of Pharmaceutical Policy and Practice 2018 11:28
    Content type: Review Published on: